VIVAKOR

2017

ANNUAL REPORT

Dear Shareholder,

Having recently filed our Form 10-K Annual Report, Vivakor would like to take this opportunity to provide an update to our valued Shareholder partners regarding the advancement of our technology and projects. During 2017, the Company's focus was on two main areas: oil production in Utah and reclamation projects in the Middle East. We're excited about the prospects in both of these areas and believe each will deliver impressive financial results during 2018.

Vivakor was able to finalize two remediation projects in Utah, (i) SITLA Masser property and (ii) Temple Mountain mine. Additionally, Vivakor commenced production on the Crown property located on Asphalt Ridge which contains an estimated 46 million barrels of oil. We expect these projects to flourish well into the future as our technology continues to develop. We appreciate the efforts and significant government support provided by the State of Utah. Our production advancements will result in new opportunities to provide a functional change to the supply chain such as on-site upgrading of material and its potential usage as a high value asphalt binder.

Vivakor's operations in the Middle East experienced significant developments as well as challenges during 2017. Specifically, Saudi Arabia experienced a rapidly changing business and political environment due to new policies enacted by the governing Prince. These policies deeply impacted several of our Saudi business partners and, as a result, have affected our operations in Saudi Arabia. While there continues to be a significant demand for Vivakor's technology and operations in Saudi, we have made the conscious decision to focus on Kuwait until all the political changes settle in Saudi Arabia. Vivakor's recently signed project with The Energy Resource Institute (TERI) for reclamation services for Kuwait Oil Company (KOC), which project is funded by the United Nations, presents us with an enormous opportunity to participate in the world's largest oil remediation cleanup project. The initial project is scheduled to be operational in July 2018 and we expect to receive additional contracts covering the majority of the necessary oil remediation contract for the cleanup of Kuwait. Should Vivakor continue to acquire these contacts (expected to be finalized later in 2018) in Kuwait, we expect them to provide significant financial results over the next five years.

Taking both Utah and Kuwait into consideration, Vivakor believes it will achieve significant revenue streams, particularly in the third and fourth quarters of 2018, which will provide a great benefit to the company and our Shareholder partners.

We thank you for your continued support and belief in Vivakor and look forward to providing additional updates as 2018 progresses.

The following represent some of the key financial highlights reflected in the December 31, 2017 financial statements:

Category	December 31, 2017	YOY%
Current Assets	$7,026248	+66%
Investments in marketable securities	$2,500,000	+9,900%
Intellectual property, technology & patents	$21,025,000	+43%
Total Assets	$39,886,435	+27%

Respectfully,

Matthew Nicosia
Chairman & CEO
Vivakor, Inc.

VIVAKOR, INC.

ANNUAL REPORT

FOR THE YEAR

ENDED DECEMBER 31, 2017

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report contains certain forward-looking statements. These forward-looking statements, which may be identified by words including “anticipates,” “believes,” “intends,” “estimates,” “expects,” “forecasts”, “plans,”, “ projects”, and similar expressions include, but are not limited to, statements regarding (i) future plans, objectives, strategies, expenditures, results and objectives of future operations and research, (ii) proposed new products, services, developments or industry rankings; (iii) future revenue, economic conditions or performance; (iv) potential collaborative arrangements and (v) the need for and availability of additional financing.

The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties. These forward-looking statements are based on assumptions regarding our business and technology, which involve judgments with respect to, among other things, future scientific, economic and competitive conditions, and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Accordingly, undue reliance should not be placed on forward looking statements as they only represent the Company’s views as of the date the statements were made. Although we believe that the assumptions underlying the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements and actual results may differ materially from those set forth in the forward-looking statements. In light of the significant uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as representation by us or any other person that our objectives or plans will be achieved. We do not intend to and specifically decline any obligation to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments.

Table of Contents

BUSINESS

General

Our financial statements include the accounts of our company and its wholly-owned subsidiaries, VivaSight, Inc., VivaTherma, Inc. and VivaVentures, Inc., and its majority-owned subsidiaries, VivaVentures Energy Group, Inc. and HealthAmerica, Inc.

Set forth below is a brief description of the business of each of our company's active investments and subsidiaries.

VivaVentures Energy Group, Inc., a green energy alternatives and petroleum asset subsidiary

- Acquired the rights and ownership to multiple proprietary technologies and processes for a green energy oil extraction from oil sands.
- Acquired the ownership of certain material in Utah containing oil-sand deposits.
- Successfully tested and commenced developmental production with an oil sand extraction machine.
- Entered into an ore supply agreement for oil sand supply for oil production in Vernal, Utah.
- Registered for business operations and opened offices in Doha, Qatar according to our international business model for reclamation and remediation.
- Acquired a contract with The Energy Resource Institute (TERI) for a reclamation service contract with Kuwait Oil Company (KOC). The contract is a pilot program that is expected produce further tiered contracts of a United Nations program worth approximately $4 billion for the clean up of the oil spills from the Iraq Invasion.

VivaVentures, Inc., a green energy alternatives and mineral asset subsidiary

- Acquired the rights and ownership to the proprietary technology for a disruptive metallic vaporization science and process for precious metal extraction
- Acquired a 39% ownership in VivaVentures Precious Metals, LLC. Two precious metal extraction units have been developed with the proprietary extraction technology.
- Focuses on mineral and other such assets that may be extracted or leveraged.

Investment in VivaCeuticals, Inc., a natural and formulary products company

- We acquired a minority interest in VivaCeuticals, Inc. The Company also has provided secured loan financing and assistance to the development and commercialization of two bioactive beverages and one weight loss beverage, which VivaCeuticals, Inc. markets as RegeneBlend, RegeneBoost, and RegeneSlim. The company as recently ceased operations in the Unites States, and is structuring for international business. Our loans are collateralized by these formulas and other marketing software assets. Additionally, the Company receives a percentage of total gross sales of VivaCeuticals, Inc. RegeneBlend is a highly concentrated extract of natural products rich in antioxidants and other phytochemicals. RegeneBoost is a nutraceutical, bioactive beverage enriched with phytochemicals and antioxidants. The company as recently ceased operations in the Unites States, and is structuring for international business. Due to these events, the company is currently being wound down and our Company is adjusting its loan receivable based on information obtained from the investment's management. As of December 31, 2017 and 2016, the Company realized an impairment allowance in the amount of $600,342 and $791,383.

Investment in Odyssey Group International, Inc., a health and wellness product development company

- We have acquired a minority interest in Odyssey Group International, Inc. (Odyssey). The Company has also provided secured loan financing and assistance to the development and commercialization of a natural athletic enhancement beverage, which Odyssey sells to distributors to market and sell. Odyssey has also acquired the right to sell and distribute a new technology called CardioMap®, which is an advanced technology for early non-invasive testing for heart disease. The Company's loans are collateralized by the formula and assets of the company, and our Company receives a percentage of total gross sales until the loan has been repaid in full. Odyssey is a trans-disciplinary product development enterprise involved in the discovery, development and commercialization of a broad range of products applied to target industries. Odyssey is a reporting company under the Securities and Exchange Act and is trading at $1 per share. As of December 31, 2017 the Company has recognized Accumulated and Other Comprehensive Income of $2,475,000 for this investment.

Our Company's Inactive Subsidiaries

Our company has the following wholly-owned or partially-owned subsidiaries which are either inactive or are not generating material revenue:

- VivaSight, Inc., a Nevada corporation (wholly owned);
- VivaOptics, Inc., a Nevada corporation (wholly owned);
- VivaThermic, Inc., a Nevada corporation (wholly owned); and

- HealthAmerica, Inc., a Nevada corporation (approximately 62%, majority owned).

Our Products and Services

Our company intends to continue secured lending and assistance in developing existing technologies and commercial products, which include the products described below:

Petroleum. VivaVentures Energy Group, Inc. has acquired multiple proprietary technologies and processes to extract oil from different materials (i.e. oil-sands). We have developed an oil-sand extraction machine and we are currently developing it for scaled up operations. The extraction machine gives our operations a low-cost, proprietary mobile processing capability to extract high-quality, premium oil from material and other sand-based ore bodies. Patent applications have been filed and are pending for the process. The production extraction machine has successfully completed test productions and is projected to be in scaled up production in 2018. The first extraction unit in Utah continues to be developed and is in developmental testing production. We have acquired oil-sands in Utah, including approximately three hundred (300) million cubic yards of oil sand material to process. Each cubic yard yields approximately 1 barrel of oil.

In addition, there is a tremendous need for remediation for the clean-up of oil spills across the globe. With our technology, we have the ability to assist companies and governments in this effort, in particular where there is an oil spill and sand is mixed with oil. This provides us with an enormous opportunity in this multi-billion-dollar global market for clean-up of these tainted environments. Our technology adds a component to remediation that is not readily available through traditional remediation processes. We provide the ability to clean and reclaim the oil that has been spilled. This propels the Company into another market area that is not being served in the manner in which we deliver. A significant remediation project that the Company has recently acquired is for remediation services to the Kuwait Oil Company (KOC) for oil spills during the Iraq invasion. The Company will service a contract for a pilot program for between $1 million ad $2 million and is expected to receive further tiered and milestone projects for the cleanup of the spills from the Iraq invasion estimated in its entirety to be $4 billion. We are the only company currently on track for the project of remediating hydrocarbon waste from oil contaminated material through a pilot program with KOC that could result in significant revenues streams for the Company. The Company intends to finance the construction of additional extraction machines, which will increase the daily oil production and extraction services. We believe that this proprietary extraction process, when fully implemented, will revolutionize the oil industry.

The Company has agreed to loan VivaVentures Energy Group, Inc. sufficient funds to conduct its operations, including construction of additional extraction machines. The Company will be required to raise additional capital to fulfill this commitment but has not received any corresponding commitments to invest. After verification of the scaled up production results, we expect to attract substantial investment for this venture.

Mining and Minerals. We have acquired a proprietary technology which extracts precious metals from sand-based ore materials. We have also acquired a 39% interest in VivaVentures Precious Metal, LLC which operates the precious metal mining and extraction. The proprietary extraction technology uses a thermal vapor extraction process to remove and process precious metals, including gold, silver, platinum, palladium and rhodium. Since inception of this venture, our company has funded the establishment of two precious metal extraction units. This venture has produced approximately $7 million in precious metals in a concentrate flake form. The Company has received $4.1 million of these precious metals according to agreements for financing and use of the extraction technology. For the year ended December 31, 2017 the Company did not have production due to the Company assessing and testing the use of the nano-technology and machines for further application in other industries, mainly in use toward further cracking of oil production to create a diesel product. For the year ended December 31, 2016, total precious metal production was approximately $1 million, which the Company received over $600,000. The 2016 production was mainly produced from the initial thermal vaporization unit. We believe that this proprietary thermal vapor extraction process, when fully implemented, will be one of the most efficient methods of extracting precious metals in the world.

The Company has agreed to loan to VivaVentures Precious Metals, LLC sufficient funds to conduct mining ad extraction operations, and further development of process and machines, including construction of additional thermal vaporization machines. The Company will be required to raise additional capital to fulfill this commitment but has not received any corresponding commitments to invest.

Natural and Formulary Products. We have acquired a minority interest in VivaCeuticals, Inc. The Company has also provided secured loan financing and assistance to the development and commercialization of two bioactive beverages and one weight loss beverage, which VivaCeuticals, Inc. markets as RegeneBlend, RegeneBoost, and RegeneSlim. The company has recently ceased operations in the United States, but is restructuring for international business. The Company's loans are secured by the formulas and other marketing software assets, and the Company will receive a percentage of total gross sales until the loan is repaid in full. RegeneBlend is a highly concentrated extract of natural products rich in antioxidants and other phytochemicals. RegeneBoost is a nutraceutical, bioactive beverage enriched with phytochemicals and antioxidants. We also assisted in developing commercial products for cryogenic preservation and storage technology, called VivaThermic Cryovials. The Cryovials are not actively marketed, but VivaCeuticals will occasionally sell cryovials as a result of customer solicitation. The company as recently ceased operations in the Unites States, and is structuring for international business. Due to these events, the company is currently being wound down and our Company is adjusting its loan receivable based on information obtained from the investment's management. As of December 31, 2017 and 2016, the Company realized an impairment allowance in the amount of $600,342 and $791,383.

Health and Wellness Products. We have acquired a minority interest in Odyssey Group International, Inc. (Odyssey). The Company has also provided secured loan financing and assistance to the development and commercialization of a natural athletic enhancement beverage, which Odyssey sells to distributors to market and sell. Odyssey has also acquired the right to sell and distribute a new technology called CardioMap®, which is an advanced technology for early non-invasive testing for heart disease. The Company's loans are collateralized by the formula, and the Company receives a percentage of total gross sales until the loan has been repaid in full. Odyssey is a trans-disciplinary product development enterprise involved in the discovery, development and commercialization of a broad range of products applied to target industries. Odyssey is a reporting company under the Securities and Exchange Act and is trading at $1 per share. As of December 31, 2017 the Company has recognized Accumulated and Other Comprehensive Income of $2,475,000 for this investment.

Future Products; Research and Acquisition

We intend to identify, develop or acquire and bring to market products primarily in the mining and minerals, petroleum and alternative energy industries, but also as opportunities may arise in the natural and formulary products industry. Our general approach is to select products or processes that are at or near commercial viability and have a time to market of around one year. Once selected, we negotiate agreements to provide secured loan financing to complete development, testing and product launch in exchange for control of, or a significant ownership interest in, the products or companies.

We formed VivaVentures, Inc., our wholly-owned subsidiary, to conduct the operations and hold the investments in the mining and minerals industry and alternative energy industry products, companies or investments acquired in this process.

We formed VivaVentures Energy Group, Inc., a majority-owned subsidiary, to conduct the operations, manage joint ventures, and hold the investments in the petroleum industry, companies or investments acquired in this process.

Competition

Our company competes in numerous industries, all of which are believed by us to be intensively competitive. Our company's competitors have substantially greater resources, financial capabilities, marketing and sales forces and name recognition.

Governmental Regulation

The Company's petroleum and mining activities are subject to federal, state and local laws, regulations and policies, including laws regulating the removal of natural resources from the ground and the discharge of materials into the environment. These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Exploration and exploitation activities are also subject to federal, state and local laws and regulations which seek to maintain health and safety standards by regulating the design and use of exploration methods and equipment. Environmental and other legal standards imposed by federal, state or local authorities are constantly evolving, and typically in a manner which will require stricter standards and enforcement, and increased fines and penalties for non-compliance. Such changes may prevent us from conducting planned activities or increase our costs of doing so, which would have material adverse effects on our business. Moreover, compliance with such laws may cause substantial delays or require capital outlays in excess of those anticipated, thus causing an adverse effect on us. Additionally, we may be subject to liability for pollution or other environmental damages that we may not be able to or elect not to insure against due to prohibitive premium costs and other reasons. Unknown environmental hazards may exist on our mining claims, or we may acquire properties in the future that have unknown environmental issues caused by previous owners or operators, or that may have occurred naturally.

Some aspects of our company's medical, biotechnology and nutraceutical supplement businesses and product candidates are subject to some degree of government regulation. As a provider of medical and biotechnology products, we are subject to extensive regulation by, among other governmental entities, the United States Food and Drug Administration (the **"FDA"**). In addition, before selling any of our product candidates, we will be required to comply with the rules and regulations of state, local and foreign regulatory bodies in jurisdictions where we desire to sell our products. These regulations govern the introduction of new products, the observance of certain standards with respect to the manufacture, safety, efficacy and labeling of such products, the maintenance of certain records, the tracking of such products and other matters.

For some of our product candidates, and in some countries, government regulation is significant, and generally there is a trend toward more stringent regulation. In recent years, the FDA and certain foreign regulatory bodies have pursued a more rigorous enforcement program to ensure that regulated businesses like our company's businesses comply with applicable laws and regulations. We devote significant time, effort and expense addressing the extensive governmental regulatory requirements applicable to our company's businesses. To date, we have received no notifications or warning letters from the FDA or any other regulatory body of alleged deficiencies in our company's compliance with the relevant requirements, and we have not recalled or issued safety alerts with respect to any of our company's products. There can be no assurance, however, that a warning letter, recall or safety alert, if it occurred, would not have a material adverse effect on our company.

Failure to comply with applicable federal, state, local or foreign laws or regulations could subject our company to enforcement action, including product seizures, recalls, withdrawal of marketing clearances and civil and criminal penalties, any one or more of which could have a material adverse effect on our company's businesses. We believe that our company is in substantial compliance with such governmental regulations. However, federal, state, local and foreign laws and regulations regarding the manufacture and sale of medical devices are subject to future changes. There can be no assurance that such changes would not have a material adverse effect on our company.

Environmental Regulation

Some aspects of our company's mining, mineral extraction and alternative energy businesses may be subject to certain environmental laws. We have not yet determined the costs and effects of compliance with such environmental laws. Any failure by our company to comply with applicable federal, state or local environment laws could subject our company to enforcement action, including civil and criminal penalties, any one or more of which could have a material adverse effect on our company.

Employees

As of December 31, 2017, we have approximately 15 full-time or contracted employees, consisting of our CEO, CFO, and additional administrative personnel.

Principal Executive Office

Our principal executive office is located at 8565 S. Eastern Ave., Ste. 150, Las Vegas, NV 89123. Our telephone number is (949) 281-2606.

RISK FACTORS

Risks Relating to our Business

We are at a very early operational stage, and our success is subject to the substantial risks inherent in the establishment of a new business venture.

The implementation of our business strategy is in a very early stage. We are in the process of assisting in developing numerous technology candidates but none have proven to be commercially successful. Our business and operations should be considered to be in a very early stage and subject to all of the risks inherent in the establishment of a new business venture. Accordingly, our intended business and operations may not prove to be successful in the near future, if at all. Any future success that we might enjoy will depend on many factors, several of which may be beyond our control, or which cannot be predicted at this time, and which could have a material adverse effect on our financial condition, business prospects and operations and the value of an investment in our company.

We have a very limited operating history, and our business plan is unproven and may not be successful.

Although we began operations in 2008, we recently adopted a new business plan and investment strategy that has not been proven to be successful. We have not sold any substantial amount of products commercially and have not proven that our business model will allow us to identify and develop commercially feasible products or technologies.

We have suffered operating losses since inception, and we may not be able to achieve profitability.

We had an accumulated deficit of $15,957,077 as of December 31, 2017, and we expect to continue to incur significant development expenses in the foreseeable future related to the completion of development and commercialization of our products. As a result, we are incurring substantial operating and net losses, and it is possible that we never will be able to sustain or develop the revenue levels necessary to attain profitability. If we fail to generate sufficient revenues to operate profitably, or if we are unable to fund our continuing losses, you could lose all or part of your investment.

We may have difficulty raising additional capital, which could deprive us of necessary resources, and you may experience dilution or subordinate stockholder rights, preferences and privileges as a result of our financing efforts.

We expect to continue to devote significant capital resources to fund the acquisition and development of new products and processes. In order to support the initiatives envisioned in our business plan, we will need to raise additional funds through the sale of assets, public or private debt or equity financing or other arrangements. Our ability to raise additional financing depends on many factors beyond our control, including the state of capital markets, the market price of our Common Stock and the development or prospects for development of competitive technologies by others. Because our Common Stock is not listed on a national stock exchange, many investors may not be willing or allowed to purchase it or may demand steep discounts. Sufficient additional financing may not be available to us or may be available only on terms that would result in further dilution to the current owners of our Common Stock.

We expect to raise additional capital during 2018, but we do not have any firm commitments for funding. If we are unsuccessful in raising additional capital or the terms of raising such capital are unacceptable, then we may have to modify our business plan and/or curtail our planned activities and other operations.

Failure to effectively manage our growth could place strains on our managerial, operational and financial resources and could adversely affect our business and operating results.

Our growth has placed, and is expected to continue to place, a strain on our managerial, operational and financial resources. Further, if our subsidiaries' businesses grow, then we will be required to manage multiple relationships. Any further growth by us or our subsidiaries, or any increase in the number of our strategic relationships, will increase this strain on our managerial, operational and financial resources. This strain may inhibit our ability to achieve the rapid execution necessary to implement our business plan and could have a material adverse effect on our financial condition, business prospects and operations and the value of an investment in our company.

There are substantial inherent risks in attempting to commercialize new technological applications, and, as a result, we may not be able to successfully develop products or technologies for commercial use.

Our company intends to acquire or invest in products in numerous technological fields. We have limited scientific experience in some of these fields. Often development requires significant amounts of capital and takes an extremely long time to reach commercial viability, if at all. During the development process, we may experience technological barriers that we may be unable to overcome. Because of these uncertainties, it is possible that many of our product candidates may never be successfully developed. If we are unable to successfully develop products or technology for commercial use, then we will be unable to generate revenue or build a sustainable or profitable business.

We will need to achieve commercial acceptance of our products to generate revenues and achieve profitability.

Even if our efforts to acquire or develop products yields technologically feasible applications, we may not successfully develop commercial products, and even if we do, we may not do so on a timely basis. If our research efforts are successful on the technology side, it could take at least several years before this technology will be commercially viable. During this period, superior competitive technologies may be introduced or customer needs may change, which will diminish or extinguish the commercial uses for our applications. We cannot predict when significant commercial market acceptance for our products will develop, if at all, and we cannot reliably estimate the projected size of any such potential market. If markets fail to accept our products, then we may not be able to generate revenues from the commercial application of our technologies. Our revenue growth and achievement of profitability will depend substantially on our ability to introduce new products that are accepted by customers. If we are unable to cost-effectively achieve acceptance of our technology by customers, or if the associated products do not achieve wide market acceptance, then our business will be materially and adversely affected.

We expect to rely on third parties for the worldwide marketing and distribution of our product candidates, who may not be successful in selling our products.

We currently do not have adequate resources to market and distribute products worldwide and expect to engage third party marketing and distribution companies to perform these tasks. While we believe that distribution partners will be available, we cannot assure you that the distribution partners, if any, will succeed in marketing our products on a global basis. We may not be able to maintain satisfactory arrangements with our marketing and distribution partners, who may not devote adequate resources to selling our products. If this happens, we may not be able to successfully market our products, which would decrease or eliminate our ability to generate revenues.

We may lose out to larger and better-established competitors.

The industries in which we compete are intensely competitive. Most of our competitors have significantly greater financial, technical, manufacturing, marketing and distribution resources as well as greater experience in industry than we have. Competition may result in price reductions, reduced gross margins and loss of market share.

We could be damaged by product liability claims.

Some of our products are intended to be used by consumers. If one of our products malfunctions or a consumer misuses it or has a reaction to it and injury results, then the injured party could assert a product liability claim against our company. We currently do not have product liability insurance and may not be able to obtain such insurance at a rate that is acceptable to us or at all. Furthermore, even if we can obtain insurance, insurance may not be sufficient to cover all of the liabilities resulting from a product liability claim, and we might not have sufficient funds available to pay any claim over the limits of our insurance. Because personal injury claims based on product liability may be very large, an underinsured or an uninsured claim could financially damage our company.

We may indemnify our directors and officer against liability to us and holders of our securities, and such indemnification could increase our operating costs.

Our Bylaws allow us to indemnify our directors and officers against claims associated with carrying out the duties of their offices. Our Bylaws also allow us to reimburse them for the costs of certain legal defenses. Insofar as indemnification for liabilities arising under the Securities Act of 1933 (the “Securities Act”) may be permitted to our directors, officers or control persons, we have been advised by the SEC that such indemnification is against public policy and is therefore unenforceable.

Since our officers and directors are aware that they may be indemnified for carrying out the duties of their offices, they may be less motivated to meet the standards required by law to properly carry out such duties, which could increase our operating costs. Further, if our officers and directors file a claim against us for indemnification, the associated expenses could also increase our operating costs.

We are exposed to risks associated with the recent worldwide economic slowdown and related uncertainties.

We plan to expand our level of operations. Slower economic activity, concerns about inflation or deflation, decreased consumer confidence, reduced corporate profits and capital spending, adverse business conditions and liquidity concerns in the general economy and recent international conflicts and terrorist and military activity have resulted in a downturn in worldwide economic conditions, especially in the United States. Recent political and social turmoil related to international conflicts and terrorist acts can be expected to place further pressure on economic conditions in the United States and worldwide. These political, social and economic conditions make it extremely difficult for us to accurately forecast and plan future business activities. If such conditions continue or worsen, then our business, financial condition and results of operations could be materially and adversely affected.

Risks Relating to our Stock

We have issued shares of Series A Preferred Stock, which have super voting rights, permitting the holder of voting power over those shares to control a majority vote over certain business aspects.

AKMN Irrevocable Trust is the record holder of 2,000,000 shares of our Series A Preferred Stock. Matthew Nicosia, CEO, is the trustee of AKMN Irrevocable Trust, and Johnathan Nicosia (Matthew Nicosia's son) is the beneficiary. The Series A Preferred Stock provides for 25 votes for each share of Common Stock into which such shares of Series A Preferred Stock are restricted for five years from the date of issuance (restrictions remain with the stock if assigned to a third party) and currently may only be converted to Common Stock upon liquidation of the Company. With a current conversion ratio of 10 shares of Common Stock for each outstanding share of Series A Preferred Stock, this results in AKMN Irrevocable Trust (currently) having 500,000,000 votes, representing voting control of certain business aspects.

The sale of shares of our Common Stock and securities convertible into shares or our Common Stock in private placements could cause the price of our Common Stock to decline.

The trading volume in our shares of Common Stock is very small. A sale of shares at any given time could cause the trading price of our Common Stock to decline. The sale of a substantial number of shares of our Common Stock, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price at which we otherwise might desire to effect sales.

Our Common Stock is traded in the Pink Sheets, which may deprive stockholders of the full value of their shares.

Our Common Stock is approved for quotation on the Pink Sheets. Therefore, our Common Stock is expected to have fewer market makers, lower trading volumes and larger spreads between bid and asked prices than securities listed on an exchange such as the New York Stock Exchange or the NASDAQ Stock Market. These factors may result in higher price volatility and less market liquidity for our Common Stock.

A low market price would severely limit the potential market for our Common Stock.

Since trading commenced, our Common Stock has traded at a price substantially below $5.00 per share, subjecting trading in the stock to certain SEC rules requiring additional disclosures by broker-dealers. These rules generally apply to any non-FINRA equity security that has a market price share of less than $5.00 per share, subject to certain exceptions (a "penny stock"). Such rules require the delivery, before any penny stock transaction, of a disclosure schedule explaining the penny stock market and the risks associated therewith, and impose various sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and institutional or wealthy investors. For these types of transactions, the broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction before the sale. The broker-dealer also must disclose the commissions payable to the broker-dealer and current bid and offer quotations for the penny stock, and, if the broker-dealer is the sole market maker, the broker-dealer must disclose that fact and the broker-dealer's presumed control over the market. Such information must be provided to the customer orally or in writing before or with the written confirmation of trade sent to the customer. Monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. The additional burdens imposed on broker-dealers by such requirements could discourage broker-dealers from effecting transactions in our Common Stock.

FINRA sales practice requirements also may limit a stockholder's ability to buy and sell our Common Stock.

In addition to the penny stock rules promulgated by the SEC, which are discussed in the immediately preceding risk factor, FINRA rules require that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Before recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our Common Stock, which may limit the ability to buy and sell our Common Stock and have an adverse effect on the market value for our shares.

A stockholder's ability to trade our Common Stock may be limited by trading volume.

A consistently active trading market for our Common Stock may not occur on the Pink Sheets. A limited trading volume may prevent our stockholders from selling shares at such times or in such amounts as they otherwise may desire.

Our company has a concentration of stock ownership and control, which may have the effect of delaying, preventing or deterring a change of control.

Our Common Stock ownership is highly concentrated. AKMN Irrevocable Trust, of which Matthew Nicosia, our CEO, is the trustee, is the record owner of all 2,000,000 shares of our Series A Preferred Stock, which has super voting rights to control certain business aspects. As a result of the concentrated ownership of our stock, Mr. Nicosia, as the trustee of this stockholder, will be able to control all matters requiring stockholder approval, including the election of directors and approval of mergers and other significant corporate transactions. This concentration of ownership may have the effect of delaying, preventing or deterring a change in control of our company. It also could deprive our stockholders of an opportunity to receive a premium for their shares as part of a sale of our company, and it may affect the market price of our Common Stock.

We have not voluntarily implemented various corporate governance measures, in the absence of which stockholders may have more limited protections against interested director transactions, conflicts of interest and similar matters.

Recent federal legislation, including the Sarbanes-Oxley Act of 2002, has resulted in the adoption of various corporate governance measures designed to promote the integrity of corporate management and the securities markets. Some of these measures have been adopted in response to legal requirements. Others have been adopted by companies in response to the requirements of national securities exchanges, such as the NYSE or the NASDAQ Stock Market, on which their securities are listed. Among the corporate governance measures that are required under the rules of national securities exchanges and FINRA are those that address board of directors' independence, audit committee oversight and the adoption of a code of ethics. While our board of directors has adopted a Code of Ethics and Business Conduct, we have not yet adopted any of these corporate governance measures and, since our securities are not listed on a national securities exchange or NASDAQ, we are not required to do so. It is possible that, if we were to adopt some or all of these corporate governance measures, stockholders would benefit from somewhat greater assurances that internal corporate decisions were being made by disinterested directors and that policies had been implemented to define responsible conduct. For example, in the absence of audit, nominating and compensation committees comprised of at least a majority of independent directors, decisions concerning matters such as compensation packages to our senior officers and recommendations for director nominees may be made by a majority of directors who have an interest in the outcome of the matters being decided. Prospective investors should bear in mind our current lack of corporate governance measures in formulating their investment decisions.

Our board of directors has the authority to issue shares of "blank check" Preferred Stock, which may make an acquisition of our company by another company more difficult.

We have adopted and may in the future adopt certain measures that may have the effect of delaying, deferring or preventing a takeover or other change in control of our company that a holder of our Common Stock might consider in its best interest. Specifically, as of December 31, 2017, our board of directors, without further action by our stockholders, had the authority to issue up to approximately 330,638,129 additional shares of Preferred Stock (not counting the 2,000,000 shares of Series A Preferred Stock or the approximate 71,827,060 shares of Series B Preferred Stock or the 21,784,811 shares of Series B-1 Preferred Stock, and 23,750,000 shares of Series C-1 Preferred Stock) and to fix the rights (including voting rights), preferences and privileges of these shares ("blank check" Preferred Stock). Such Preferred Stock may have rights, including economic rights, senior to our Common Stock. As a result, the issuance of the Preferred Stock could have a material adverse effect on the price of our Common Stock and could make it more difficult for a third party to acquire a majority of our outstanding Common Stock.

Because we will not pay dividends on our Common Stock in the foreseeable future, stockholders will only benefit from owning Common Stock if it appreciates.

We have never paid cash dividends on our Common Stock, and we do not intend to do so in the foreseeable future. We intend to retain any future earnings to finance our growth. Accordingly, any potential investor who anticipates the need for current dividends from his investment should not purchase our Common Stock.

PROPERTIES

We currently lease executive office space in Las Vegas, Nevada; Cottonwood Heights, Utah; and Irvine, California. The monthly base rent for these offices is approximately $22,000. Additionally, the company has VivaThermic offices in Des Moines, Iowa and an executive office in Las Vegas, Nevada. We believe these facilities are in good condition, but that we may need to expand our leased space as needs increase.

LEGAL PROCEEDINGS

As of the date of this report, the Company is not party to any legal proceedings.

MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our stock trades on the Pink Sheets under the symbol "VIVK". The following table sets forth the bid prices quoted for our common stock during each quarter since our stock began trading, as reported by the Pink Sheets, LLC. The following quotations reflect inter-dealer prices, without retail mark-up, markdown or commission and may not necessarily represent actual transactions. The following quotations also include the effects of any reverse and forward stock splits that may have occurred.

Fiscal Year Ended December 31, 2017	High	Low
Fourth Quarter	$ 0.54	$ 0.27
Third Quarter	0.55	0.20
Second Quarter	0.60	0.25
First Quarter	$ 0.65	$ 0.30

Fiscal Year Ended December 31, 2016	High	Low
Fourth Quarter	$ 0.60	$ 0.15
Third Quarter	0.40	0.12
Second Quarter	0.13	0.11
First Quarter	$ 0.28	$ 0.07

Transfer Agent

The Company's transfer agent is Empire Stock Transfer, 1859 Whitney Mesa Drive, Henderson, Nevada 89014 (702) 818-5898.

Holders of Common Stock

Our stockholder list contains the names of approximately 125 registered stockholders of record of the Company's Common Stock on December 31, 2017. This number does not include beneficial owners of our common stock whose shares are held in the names of various dealers, clearing agencies, banks, brokers and other fiduciaries.

Dividends and Stock Repurchases

We have never paid cash dividends on our common stock and do not anticipate paying such dividends in the foreseeable future. The payment of dividends, if any, will be determined by the Board of Directors in light of conditions then existing, including our financial condition and requirements, future prospects, restrictions in financing agreements, business conditions and other factors deemed relevant by the Board of Directors.

Purchases of Equity Securities

For the year ended December 31, 2016, we repurchased 122,000 shares of our Common Stock, which is reflected in and carried at cost on our financial statements.

Securities Authorized for Issuance Under Equity Compensation Plans

The Company has issued 9,000 shares of common stock under its equity compensation plans. The Company has adopted two equity incentive plans, one in 2008 (the "2008 Plan") and one in 2010 (the "2010 Plan"). Pursuant to the 2008 Plan, the Company was authorized to issue up to 7,500,000 shares of common stock and pursuant to the 2010 Plan was authorized to issue an additional 50,000,000 shares. The Company issued options to purchase 600,000 shares under the 2008 Plan, none of which were exercised, and awards of 9,000,000 shares under the 2010 Plan. In March 2011, the Company effectuated a 1 for 1,000 share reverse split, which effectively reduced the number of shares available for issuance under the 2008 Plan to 7,500 shares, all of which are available for issuance, and 50,000 shares under the 2010 plan, of which 41,000 remain available for issuance.

Sales of Unregistered Securities

As of December 31, 2017, $1,544,373 of Preferred Stock was converted into 7,556,028 shares of Common Stock.

As of December 31, 2017, the Company issued 1,907,500 shares of Series B Preferred Stock for $381,500 cash.

As of December 31, 2017, the Company issued 12,500 shares of Series B-1 Preferred Stock for a reduction in liabilities of $3,125.

As of December 31, 2017, the Company has issued 8,432,823 shares of Series B-1 Preferred Stock as a $2,108,204 stock interest distribution to Series B Preferred Shareholders.

On September 5, 2017, the Company issued 11,250,000 shares of Series C-1 Preferred Stock related to the purchase of intellectual property, including the patents and technology relating to ammonia synthesis, FeNix coating, and other patents relating to nano-particle application. The Company also purchased a license to use a Nano Sponge technology.

As of December 31, 2016, $580,675 of Preferred Stock was converted into 1,527,527 shares of Common Stock.

For the year ended December 31, 2016, the Company issued 8,126,900 shares of Series B Preferred Stock for $1,625,004 cash.

For the year ended December 31, 2016, the Company has issued 7,093,093 shares of Series B-1 Preferred Stock as a $1,773,273 stock interest distribution to Series B Preferred Shareholders.

On September 28, 2016 the Company issued 12,500,000 shares of Series C-1 Preferred Stock for the joint rights to use, make, sell, and exploit an oil extraction and remediation technology and any patents or trade secrets related to the technology.

On January 22, 2016, our majority owned subsidiary's shareholder converted its minority interest ($10,000,000) into 20,000,000 shares of Vivakor Common Stock.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our consolidated financial statements and other financial information appearing elsewhere in this Annual Report. In addition to historical information, the following discussion and other parts of this Annual Report contain forward-looking information that involves risks and uncertainties.

Plan of Operation

The Company intends to continue secured lending services and investments to current technology development, while developing a business plan and strategy to acquire or invest in new technologies in the mining and mineral, petroleum, alternative energy and natural products industries.

We intend to invest in the companies or persons who have designed or invented such products and technologies, and retain them to continue product development, marketing and sale

Liquidity and Capital Resources

As of December 31, 2017, the Company had approximately $342,000 in cash, $4.1 million in precious metals concentrate, $2.5 million in marketable securities, and $39,000 in deposits. As of December 31, 2017, current liabilities consisted of approximately $110,000 in accounts payable, $825,000 in notes payable, and $5,000 in oil working interest payables.

Cash and cash equivalents decreased by approximately $668,000 for the year ended December 31, 2017. The decrease in cash is attributed to net effect of the following material events:

Net cash used by operating activities as of December 31, 2017 was approximately $397,000, which is mainly due to the net effect of a net loss of ($1.9 million), amortization and depreciation ($883,000), an impairment loss ($600,000), and a decrease of accounts receivable ($154,000), and a decrease in working interest payables ($1.7 million).

Net cash used by investing activities as of December 31, 2017 was approximately $377,000, and is due to the purchase of equipment for additions for the development of the oil extraction machine.

Net cash provided by financing activities as of December 31, 2017 was approximately $107,000, and is due to the net effect of the Company issuing Preferred Series B shares for cash ($382,000), issuance of production contracts ($2.1 million), issuance of notes payable ($702,000), payment on working interest contracts ($39,000) and further investment in ongoing technologies and investments in the mining and minerals, petroleum, alternative energy, and health and wellness industries ($697,000) and payments or issued pass through tax deductions on working interest contracts on ($2.4 million).

On December 2013, the Company commenced a private offering of Series B Preferred Stock, from which the Company intends to raise approximately $10,000,000 by issuing 98,000,000 shares of 12.5% Cumulative Redeemable Series B Preferred Stock at $0.20 per share. This offering was closed in March 2017. In February 2017, the Company commenced a private offering and intends to raise approximately $10,000,000 by issuing Secured Convertible Bridge Notes with a convertible price at $0.25 to the Company's Common Stock after 12 months. This offering was revised in June 2017, in which the convertible price was revised to $0.40 per share for new investment in the bridge notes.

We do have sufficient cash on hand to fund our administrative and marketing functions, but we do not have sufficient cash on hand to fund our proposed investments in precious metals technology and oil production and reclamation expansion for the next twelve months. In order to meet our obligations as they come due and to fund the expansion of our asset acquisition strategy, we will require new funding to pay for these expenses. We may do so through loans from current stockholders, public or private equity or debt offerings, grants or strategic arrangements with third parties, and we intend to and are in the process of seeking out possible international capital raising efforts through the London Stock Exchange. There can be no assurance that additional capital will be available to the Company. We currently have no agreements, arrangements or understandings with any person to obtain additional funds through bank loans, lines of credit or any other sources.

We have no material commitments or contractual purchase obligations for the next twelve, months other than the amounts that may be agreed to under our acquisition agreements relating to our mining operations.

Significant Accounting Policies

Our consolidated financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

See Note 2 in the accompanying financial statements where reference is made to the Company's significant accounting policies.

Impact of New Accounting Pronouncements

Information regarding recent accounting pronouncements that may impact our business is contained in Note 2 to consolidated financial statements, if any are present. Such financial statements are attached to this Annual Report.

Results of Operations

Comparison of the years ended December 31, 2017 and 2016

As of December 31, 2017, the Company had a net loss of approximately $1.9 million compared to net loss of $1 million as of December 31, 2016. The decrease is mainly attributed to the Company having a decrease in precious metals production. The Company is researching and adapting the nano-technology in order to use it in its Utah oil sand production in order to research and develop for oil and diesel products from current developmental production. Operating expenses increased from approximately $1.6 million for the year ended December 31, 2016 to $2.1 million for the year ended December 31, 2017. The increase in operating expenses is attributed to an increase in sales and marketing expense from private placement expenses that are generating the funding for the projects. Other income was recognized in 2017 for $167,000 due to the extinguishment of the grant payable to Iowa.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

FINANCIAL STATEMENTS

Attached are the unaudited consolidated financial statements of the Company for the year ended December 31, 2017. See the Index to Financial Statements at page F-1.

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Directors

We currently have two members of the Board of Directors and have three vacancies on the Board. We anticipate filling such vacancies as qualified candidates are identified and agree to serve. We have not yet identified any candidates.

Matthew Nicosia. From 2000 to 2007, prior to joining the Company as Executive Chairman of the Board, Mr. Nicosia co-founded Quantum Sphere, Inc. and served as a director until 2004. Mr. Nicosia also currently sits on the Board of Directors and is a director of several private companies. Mr. Nicosia received his Bachelor of Arts degree from Brigham Young University and an MBA degree from Pepperdine University.

Pablo Penaloza. Mr. Penaloza is a 15-year veteran of the banking industry and has managed international assets of $1 Billion. Mr. Penaloza has an MBA from Brigham Young University. As a native of Argentina, Mr. Penaloza speaks Spanish and Portuguese fluently and runs Vivakor's Latin American acquisition group.

Executive Officers

Name	Age	Position
Matthew Nicosia	43	Executive Chairman of the Board, Chief Executive Officer and Secretary
Tyler Nelson	37	Chief Financial Officer

Family Relationships. There are no family relationships among the directors and executive officers of the Company.

Code of Ethics

We have adopted a code of business conduct and ethics that applies to our directors, officers and all employees. The code of business conduct and ethics is posted on our website at www.vivakor.com. The code of business conduct and ethics may be also obtained free of charge by writing to us at our corporate headquarters

EXECUTIVE COMPENSATION

The following summary compensation table sets forth information concerning compensation for services rendered in all capacities during our past two fiscal years awarded to, earned by or paid to each of the following individuals. Salary and other compensation for these officers and employees are set by the Board of Directors, except for employee compensation which is set by officers of the Company.

(2) **(1)**

Name and Principal Position	Year	Salary	Bonus	Option Awards	All Other Compensation	Total Compensation
Matt Nicosia	2017	$ 50,000	$ 0	$ 0	$ 0	$ 0
Exec. Chairman of the Board, CEO	2016	$ 50,000	$ 0	$ 0	$ 0	$ 0

None of the executive officers have a written employment agreement.

Outstanding Equity Awards at Fiscal Year End

The Company has not issued any equity awards during 2017 and all prior equity awards have been either fully exercised, relinquished or extinguished by their terms, except 9,000 shares warded pursuant to the Company's 2010 Equity Compensation Plan.

Director Compensation

Our directors do not receive any consideration for their services.

Audit, Compensation and Nominating Committees

As noted above, our common stock is listed on the Pink Sheets, which does not require companies to maintain audit, compensation or nominating committees. Considering the fact that we are an early stage company, we do not maintain standing audits, compensation or nominating committees. The functions typically associated with these committees are performed by the entire Board of Directors which currently consists of two members none of which are considered independent.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Beneficial Ownership of Common Stock

The following table sets forth, to the knowledge of the Company, certain information regarding the beneficial ownership of the Company's Common Stock as of December 31, 2017 by (i) each person known by the Company to be the beneficial owner of more than 5% of the outstanding Common Stock, (ii) each of the Company's directors, (iii) each of the named executive officers in the Summary Compensation Table and (iv) all of the Company's executive officers and directors as a group. Except as indicated in the footnotes to this table, the Company believes that the persons named in this table have sole voting and investment power with respect to the shares of Common Stock indicated.

Directors, Officers and 5% Stockholders	Shares of Common Stock Beneficially Owned	Percent of Common Stock Beneficially Owned	Shares of Series A Preferred Stock Beneficially Owned	Percent of Series A Preferred Stock Beneficially Owned
AKMN Irrevocable Trust(1)(2)(3)	160,101,110	66.79%	2,000,000	100.00%
Matt Nicosia(1)(3)	78,500	*		

(1) The address for these stockholders is: c/o Vivakor, Inc., 8565 S. Eastern Ave., Ste 150, Las Vegas, NV 89123.
(2) Matt Nicosia is the trustee of the Trust, of which Johnathan Nicosia is the beneficiary. Matt Nicosia disclaims beneficial ownership of these shares.
(3) Restricted stock. In accordance with laws and regulations set forth by the Securities Exchange Commission, restricted stock remains restricted even when assigned to a third party.
* Less than 1%

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

It is our practice and policy to comply with all applicable laws, rules and regulations regarding related-person transactions, including the Sarbanes-Oxley Act of 2002. A related person is an executive officer, director or more than 5% stockholder of Vivakor, including any immediate family members, and any entity owned or controlled by such persons. Our Board of Directors (excluding any interested director) is charged with reviewing and approving all related-person transactions, and a special committee of our Board of Directors is established to negotiate the terms of such transactions. In considering related-person transactions, our Board of Directors takes into account all relevant available facts and circumstances.

Related Party Transactions

The Company has a common officer with VivaCeuticals, Inc. As of December 31, 2017 and December 31, 2016 the Company had notes receivable from VivaCeuticals, Inc., in the amount of $1,801,026 and $3,182,750 in a secured lending agreement. Vivaceuticals is being wound down, and the Company has written the receivable down due to the estimated amounts expected to be returned based on available information as Vivaceuticals completes this process. As of December 31, 2017 and 2016, the Company realized an impairment allowance in the amount of $600,342 and $791,383.

Director Independence

Our Board of Directors has adopted the definition of "independence" as described under the Sarbanes-Oxley Act of 2002 (Sarbanes-Oxley) Section 301, Rule 10A-3 under the Securities Exchange Act of 1934 (the Exchange Act) and NASDAQ Rules 4200 and 4350. Our Board of Directors has determined that none of its members meet the independence requirements.

ISSUER CERTIFICATION

I, Matt Nicosia, Chief Executive Officer of Vivakor, Inc., certify that:

1. I have reviewed this Annual Report of Vivakor, Inc.
2. Based on my knowledge, this Annual Report does not contain any untrue statement of material fact or omit to state any fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the Annual Report; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this Annual Report, fairly present in all material respects the financial condition, results of operations and cash flows of Vivakor, Inc. as of, and for, the periods presented in this Annual Report.

April 2, 2018

____

Matt Nicosia, CEO

VIVAKOR, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Consolidated Financial Statements of Vivakor, Inc.

See accompanying notes to the consolidated financial statements.

VIVAKOR, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)

	December 31, 2017	December 31, 2016
ASSETS		
Current assets:		
Cash and cash equivalents	$ 341,520	$ 1,009,684
Precious metals concentrate	4,145,494	3,022,823
Marketable securities	2,500,000	-
Accounts receivable	-	154,027
Deposits	39,234	39,234
Total current assets	7,026,248	4,225,768
Property and equipment, net	7,625,220	8,496,486
Royalty participation rights, net	180,556	222,222
License agreements, net	1,962,500	-
Intellectual property, net	18,881,944	14,437,500
Notes receivable	4,209,967	3,202,744
Other investments	-	874,456
Total assets	$ 39,886,435	$ 31,459,176
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	$ 110,105	$ 2,600
Grant payable	-	166,789
Notes payable	825,067	267,484
Working interest payable- oil contracts	4,714	871,067
Total current liabilities	939,886	1,307,940
Long term notes payable	2,500,000	-
Deferred revenue- oil production contracts	21,813,714	4,508,527
Total liabilities	25,253,600	5,816,467
Stockholders' equity:		
Preferred stock, $.001 par value; 450,000,000 shares authorized; Series A- 2,000,000 issued and outstanding for 2017 and 2016	2,000	2,000
Series B- 12.5%, cumulative, 71,827,060 and 76,182,060 issued and outstanding	71,827	76,182
Series B-1- 21,784,811 and 34,632,916 issued and outstanding	21,785	34,633
Series C-1- 23,750,000 issued and outstanding	23,750	-
Common stock, $.001 par value; 1,250,000,000 shares authorized; 239,702,491 and 230,383,377 were issued and outstanding as of 2017 and 2016	239,702	230,383
Treasury stock, at cost	(19,990)	(19,990)
Additional paid-in capital, preferred stock	30,411,844	24,969,935
Additional paid-in capital, common stock	17,482,714	16,782,259
Accumulated other comprehensive income	(17,683,635)	(4,395,857)
Accumulated deficit	(15,957,077)	(12,076,809)
Non-controlling interest	39,915	39,973
Total stockholders' equity	14,632,835	25,642,709
Total liabilities and stockholders' equity	$ 39,886,435	$ 31,459,176

See accompanying notes to the consolidated financial statements.

VIVAKOR, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

	Year Ended December 31, 2017	Year Ended December 31, 2016
Revenues	$ 50,406	$ 686,068
Cost of revenues	-	69,656
Gross profit	50,406	616,412
Operating expenses:		
Sales and marketing	296,802	7,989
General and administrative	382,911	270,530
Impairment loss	600,342	791,383
Amortization and depreciation	886,759	582,110
Total operating expenses	2,166,814	1,652,012
Income (loss) from operations	(2,116,408)	(1,035,600)
Net realized loss on oil contracts	(25,279)	(1,647)
Other income- state grant extinguished	166,789	-
Interest income	61,384	2,917
Interest expense	(44,041)	(24,300)
Earnings (loss) before income taxes	(1,957,555)	(1,058,630)
Provision for income taxes	(800)	(800)
Net income (loss)	(1,958,355)	(1,059,430)
Less: Subsidiary net income (loss) attributable to the noncontrolling interest	(10)	(4)
Net income (loss) attributable to Vivakor, Inc.	$ (1,958,345)	$ (1,059,426)
Basic earnings per share	$ (0.02)	$ (0.01)
Diluted earnings per share	$ (0.01)	$ (0.01)
Weighted average shares - Basic	223,984,928	217,273,330
Weighted average shares - Diluted	361,175,321	348,088,306

See accompanying notes to the consolidated financial statements.

VIVAKOR, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)

	Year Ended December 31,	
	2017	**2016**
Net income (loss) attributable to Vivakor, Inc.	$ (1,958,345)	$ (1,059,426)
Other comprehensive income (loss):		
Unrealized gain (loss) on precious metal concentrate, net of tax	453,235	(518,358)
Unrealized loss on oil production contracts	(20,760,282)	(5,524,129)
Unrealized loss on contingent oil production notes payable	(2,667)	(792)
Unrealized gain on available-for-sale securities, net of tax	1,856,250	-
Total other comprehensive loss	(18,453,464)	(6,043,279)
Comprehensive loss	$ (20,411,809)	$ (7,102,705)

See accompanying notes to the consolidated financial statements.

VIVAKOR, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited)

	Preferred Stock			Common Stock							
	Shares	Amount	Additional Paid-in Capital	Shares	Amount	Additional Paid-in Capital	Treasury Stock	Accum. Other Comp. Income	Accum. (Deficit)	Non-controlling Interest	Equity
January 1, 2016	81,818,384	$ 81,820	$ 17,453,328	206,893,350	$ 206,893	$ 6,210,074	-	$ (925,269)	$ (9,244,110)	$ 10,039,977	$ 23,822,713
Conversion of subsidiary shares to Preferred Stock	-	-	-	20,000,000	20,000	9,980,000	-	-	-	(10,000,000)	-
Conversion of Preferred Stock to Common Stock	(2,873,301)	(2,873)	(577,802)	3,240,027	3,240	577,435	-	-	-	-	-
Conversion of Preferred Stock to production contracts	(1,500,000)	(1,500)	(298,500)	-	-	-	-	-	-	-	(300,000)
Issuance of stock for a reduction in liabilities	150,000	150	29,850	250,000	250	14,750	-	-	-	-	45,000
Issuance of Preferred Stock for cash	8,126,900	8,126	1,616,878	-	-	-	-	-	-	-	1,625,004
Interest distributions- Preferred Stock	7,093,093	7,092	1,766,181	-	-	-	-	-	(1,773,273)	-	-
Issuance of Preferred Stock for intellectual property	20,000,000	20,000	4,980,000	-	-	-	-	-	-	-	5,000,000
Treasury Stock	-	-	-	-	-	-	(19,990)	-	-	-	(19,990)
Net income	-	-	-	-	-	-	-	-	(1,059,426)	(4)	(1,059,430)
Other comprehensive income	-	-	-	-	-	-	-	(3,470,588)	-	-	(3,470,588)
December 31, 2016	112,815,076	112,815	24,969,935	230,383,377	230,383	16,782,259	(19,990)	(4,395,857)	(12,076,809)	39,973	25,642,709
Conversion of Preferred Stock to Common Stock	(7,556,028)	(7,556)	(1,536,817)	7,556,028	7,556	1,536,817	-	-	-	-	-
Issuance of Preferred Stock for cash	1,907,500	1,908	379,592	-	-	-	-	-	-	-	381,500
Conversion of debt to Stock	12,500	13	3,112	3,763,086	3,763	161,638	-	31,628	-	-	200,154
Interest distributions- Preferred Stock	8,432,823	8,432	2,099,772	-	-	-	-	-	(2,108,204)	-	-
Issuance of Preferred Stock for intellectual property and intangible assets	11,250,000	11,250	4,488,750	-	-	-	-	-	-	-	4,500,000
Conversion of Preferred Stock B-1 to C-1	(7,500,000)	(7,500)	7,500	-	-	-	-	-	-	-	-
Working interest contract adjustments	-	-	-	-	-	-	-	-	186,281	-	186,281
SITLA contract restructure	-	-	-	(2,000,000)	(2,000)	(998,000)	-	-	-	-	(1,000,000)
Net loss	-	-	-	-	-	-	-	-	(1,958,345)	(58)	(1,958,403)
Other comprehensive income	-	-	-	-	-	-	-	(13,319,406)	-	-	(13,319,406)
December 31, 2017	119,361,871	$ 119,362	$ 30,411,844	239,702,491	$ 239,702	$ 17,482,714	$ (19,990)	$ (17,683,635)	$ (15,957,077)	$ 39,915	$ 14,632,835

See accompanying notes to the consolidated financial statements

VIVAKOR, INC.
CONSOLIDATED STATEMENT OF CASHFLOWS
(Unaudited)

		Year Ended December 31,		
		2017		**2016**
OPERATING ACTIVITIES:				
Net loss	$	(1,958,403)	$	(1,059,430)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:				
Depreciation and amortization		883,235		588,791
Impairment loss		600,342		791,383
Deferred tax asset		-		44,354
Changes in operating assets and liabilities:				
Accounts receivable		154,027		107,783
Precious metal concentrate		-		(607,293)
Accounts payable		(59,284)		768,857
Accrued interest on notes receivable		(61,384)		(2,917)
Accrued interest on notes payable		44,041		24,300
Net cash used in operating activities		(397,426)		655,828
INVESTING ACTIVITIES:				
Purchase of equipment		(377,247)		(453,313)
Purchase of other investments and securities		-		(1,233,635)
Net cash used in investing activities		(377,247)		(1,686,948)
FINANCING ACTIVITIES:				
Issuance of notes receivable		(696,725)		(1,126,214)
Payment of notes payable		(19,693)		(98,362)
Payment on working interest contracts		(2,439,823)		(29,320)
Issuance of production contracts		2,179,000		621,138
Issuance of notes payable		702,250		37,500
Issuance of preferred stock		381,500		1,640,004
Purchase of treasury stock		-		(19,990)
Net cash provided by financing activities		106,509		1,024,756
Net decrease in cash and cash equivalents		(668,164)		31,951
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		1,009,684		1,041,635
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	341,520	$	1,009,684
SUPPLEMENTAL CASHFLOW INFORMATION:				
Cash paid for interest on notes payable	$	2,364	$	305
Noncash transactions**:**				
Preferred Stock converted to Common Stock	$	1,544,373	$	580,675
Common stock issued for a reduction in liabilities	$	168,526	$	30,000
Series B Preferred shares issued for a reduction of liabilities	$	-	$	150,00
Series B Preferred shares converted to oil production contracts	$	-	$	300,000
Stock interest distribution to Series B Preferred shareholders	$	2,108,204	$	1,773,273
Series C-1 Preferred shares issued for intellectual property	$	4,500,000	$	5,000,000

See accompanying notes to the consolidated financial statements

VIVAKOR, INC.
NOTES TO THE CONSOLDIATED FINANCIAL STATEMENTS
(Unaudited)

1. Organization and Basis of Presentation

Vivakor, Inc. (collectively “we,” “us,” “our,” “Vivakor” or the “Company”) is a Nevada corporation with offices in Las Vegas, Nevada, Pleasant Hill, Iowa and Irvine, California and is an asset acquisition company that develops and acquires assets that generate revenue currently or in the near term. The Company acquires technologies and assets in the fields of precious minerals, petroleum, biotechnology, and alternative energy.

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission. In the opinion of management, all adjustments considered necessary for a fair presentation have been included.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Vivakor, Inc., its wholly-owned and majority owned active subsidiaries or joint ventures (collectively, the “Company”). Intercompany balances and transactions between consolidated entities are eliminated.

Prior Period Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation.

Accounts Receivable

Accounts receivables are carried at original invoice amount less an estimated allowance for doubtful accounts, if deemed necessary by management, and based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts, if any, by identifying troubled accounts and by using historical experience applied to an aging of accounts. No allowance for doubtful accounts was considered necessary by management as of December 31, 2017.

Precious Metal Concentrate

Precious metal concentrate includes metal concentrates located either at the Company’s facilities or in transit to its customer’s port. Concentrates consist of gold, silver, platinum, palladium and rhodium. Interest in precious metals are received as payment in commodity for interest in production from operating and lending agreements on production and are acquired at the market price. Precious metal concentrate reserves are evaluated on a quarterly basis and valued at quoted market value prices. Adjustments typically do not vary materially from production estimates; however, mark-to-market price adjustments could vary materially based on the precious metals market.

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation. Property includes mineral rights that we own. Equipment includes precious metal extraction machines, other equipment, and construction-in-process of oil extraction production machines. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. As of December 31, 2017 and 2016, $248,513 and $248,513 depreciation expense was recognized. No depreciation expense was realized for the oil extraction machine as it is still considered under construction and in development and has not been placed into scaled up production.

Equity Method Investments

Consolidated net income includes the Company’s proportionate net income or loss of equity investments. The carrying value of the Company’s equity method investments is increased and decreased by the Company’s proportionate share of the net income or loss and other comprehensive income (“OCI”) of the investee. The carrying value of our equity method investment is also decreased by dividends the Company receives from the investee. As of December 31, 2017, the

Company had an investment in the joint venture, VivaRRT, LLC, which is winding down its joint operations. The Company was originally accounting for such investment using the equity method, but due to the winding down of the joint operations the Company will account for such in "other investments" on the cost basis. The joint venture agreement provides that all joint venture losses are attributed to the Company until certain loan or the basis to the Company is repaid. Such losses and expenses generated from oil industry operations in the current year of VivaRRT, LLC will continue to be passed through to investors participating in the Company's royalty programs.

Cost Method Investments

Initial investments in equity securities are recorded at cost and subsequently adjusted to fair value if fair value is readily determinable; otherwise, the investment remains at cost. As of December 31, 2017, the Company has a non-controlling interest in the following entities: VivaVentures Precious Metals, LLC (approximately 39%), a private company, and Odyssey Group International, Inc. (approximately 2%). As of December 31, 2017, the Company is considered to hold a non-controlling interest in VivaVentures Precious Metals LLC due to the lack of voting rights that are carried with its 39% interest, and the investee's management is independent of the Company. The Company does not exercise significant influence over these investees, and the investments are accounted for using the cost method and included in "Other investments".

Convertible Instruments

The Company reviews the terms of convertible debt and preferred stock for indications requiring bifurcation, and separate accounting for the embedded conversion feature. Generally, embedded conversion features where the ability to physical or net-share settle the conversion option is not within the control of the Company or the number of shares is variable are bifurcated and accounted for as derivative financial instruments. (See Derivative Financial Instruments below). Bifurcation of the embedded derivative instrument requires allocation of the proceeds first to the fair value of the embedded derivative instrument with the residual allocated to the host instrument. The resulting discount to the debt instrument or to the redemption value of convertible preferred securities is accreted through periodic charges to interest expense over the term of the note or to dividends over the period to earliest conversion date using the effective interest rate method, respectively.

Derivative Financial Instruments

The Company does not use derivative financial instruments to hedge exposures to cash-flow or market risks. However, certain other financial instruments, such as warrants to purchase the Company's common stock and the embedded conversion features of debt and preferred instruments that are not considered indexed to the Company's common stock are classified as liabilities when either (a) the holder possesses rights to net-cash settlement, (b) physical or net share settlement is not within the control of the Company, or (c) based on its anti-dilutive provisions. In such instances, net-cash settlement is assumed for financial accounting and reporting. Such financial instruments are initially recorded at fair value and subsequently adjusted to fair value at the close of each reporting period. Fair value for option-based derivative financial instruments is determined using the Black-Scholes Option Pricing Model.

Other convertible instruments that are not derivative financial instruments are accounted for by recording the intrinsic value of the embedded conversion feature as a discount from the initial value of the instrument and accreting it back to face value over the period to the earliest conversion date using the effective interest rate method.

Revenue Recognition

The Company recognizes revenue when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the fees earned can be readily determined; and (iv) collectability of the fees is reasonably assured. The Company recognizes revenue from research contracts as services are performed under the agreements. The Company records grant revenues as the expenses related to the grant projects are incurred. Up front license fee revenues are deferred and recognized over the term of the license on a straight-line basis.

Earnings Per Share

Basic earnings per share is calculated by subtracting any preferred interest distributions from net income, all divided by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted earnings per common share is computed by dividing the net income by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method if their effect is dilutive.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

3. Marketable Securities

Marketable securities consist of equity securities recorded at fair value. Fair value is defined as the price that would be received to sell an asset in an orderly transaction between market participants at the measurement date. Valuations for marketable securities are based on quoted prices for identical assets in active markets.

4. Notes Receivable

The Company has lending agreements for investments that state the Company is to receive an interest in production or sales until the notes are paid in full. Notes receivable from these lending agreements were $4,209,967 and $2,864,996 as of December 31, 2017 and 2016.

5. Convertible Notes Payable

As of December 31, 2017 and 2016, the Company carried notes payable that may convert to stock in the amount of $788,006 and $206,626. The notes convert at the holder's option after 1 year of issuance, and may be converted into shares of common stock.

The conversion price for all convertible notes is generally equal to 10% of the average of the lowest three closing bid price on the Over-the-Counter Bulletin Board in the ten-day trading period prior to the date of the notice of conversion, or specified per share conversion rate a noted in the debt agreements, which ever less. The note may be prepaid without the holder's consent.

6. Working Interest Oil Contract

As of December 31, 2017 and 2016, the Company carried working interest payables and deferred revenue related to an oil contract for guaranteed production of between 15% and 25% of 1,500,000 barrels of oil. Whereas the percentage of production received is determined by each investors percentage of units owned in the contract, as well as the selling price of oil. When oil is below $50 the investor receives a rate of 15%. When the selling price of oil is at or above $50 the investor receives a rate of 25%. The payable, accounted for as deferred revenue, on the oil production is marked to market every quarter according to the selling price of oil on the last day of the quarter, with the difference from the cost of each barrel of oil contracted for sale through this contract by the Company, is recorded in accumulated and other comprehensive income. Upon the production and sale of oil, the Company realizes gross oil sales in revenues, and distributes cash payment for each investors' percentage in the production to the investors with the Company realizing any gain or loss on the contracted oil sales in other comprehensive income and net realized gains or loss on the Statement of Operations. As of December 31, 2017 and 2016 the Company realized a net realized loss on oil contracts of $25,279 and $1,647. As of December 31, 2017, the Company carries deferred revenue of $21,813,714 related to the working interest oil contract. For the year ended December 31, 2017 and 2016, the company distributed $2,402,971 and $1,800,472 in working interest pass through expenses or payments to investors and carries a remaining working interest liability of $4,714 and $577,402.

The contract calls for variable monthly working interest budget payments. The working interest investors will receive pass through expenses or cash repayment of working interest budget payments on or before maturity of the contract. The life of each contract is dependent on the level of production each year and is estimated to have a life of 20 years.

7. Stockholders' Equity

Series A, Series B, Series B-1, and Series C-1 Preferred Stock

The Company is authorized to issue 450,000,000 shares of preferred stock. The Company has issued 2,000,000 shares of Series A Preferred Stock. Shares of Series A Preferred Stock are restricted for 5 years from the date of issuance, and currently may only be converted to Common Stock upon liquidation of the Company (with a current conversion ratio of 10 shares of Common Stock for each outstanding share of Series A Preferred Stock), and such restrictions remain with these shares even if the stock were assigned to a third party. The conversion price is subject to adjustment under certain customary circumstances, including as a result of stock splits and combinations, dividends and distributions and certain issuances of common stock. Holders of shares of Series A Preferred Stock will have the right to 25 votes for each share of Common Stock into which such shares of Series A Preferred Stock can then be converted (with a current conversion ratio of 10 shares of Common Stock for each outstanding share of Series A Preferred Stock) and the right to a liquidation preference. Holders of shares of Series A Preferred Stock are not currently entitled to dividends. The Company has the right, but not the obligation, to redeem shares of Series A Preferred Stock.

The Company has issued 71,827,060 and 76,182,060 of Series B Preferred Stock as of December 31, 2017 and 2016. Shares of Series B Preferred Stock are convertible one year after issuance, at any time at the option of the holder, into shares of Common Stock (with a current conversion ratio of one share of Common Stock for each outstanding share of Series

B Preferred Stock). In addition, automatic conversion of shares of Series B Preferred Stock into shares of Common Stock may occur due to public offerings entered into or by written consent of a majority of the holders of Series B Preferred Stock. The conversion price is subject to adjustment under certain customary circumstances, including as a result of stock splits and combinations, dividends and distributions and certain issuances of common stock. The Company has the right, but not the obligation, to redeem shares of Series B Preferred Stock one year after issuance. Holders of Series B Preferred Stock will have the right to one vote for each share. Dividends are 12.5% and cumulative and are payable only when, as and if declared by the Board of Directors.

The Company has issued 21,784,811 and 34,632,916 of Series B-1 Preferred Stock as of December 31, 2017 and 2016. Shares of Series B-1 Preferred Stock are convertible one year after issuance, at any time at the option of the holder, into shares of Common Stock (with a current conversion ratio of one share of Common Stock for each outstanding share). In addition, automatic conversion of shares of Series B-1 Preferred Stock into shares of Common Stock may occur due to public offerings entered into or by written consent of a majority of the holders of Series B-1 Preferred Stock. The conversion price is subject to adjustment under certain customary circumstances, including as a result of stock splits and combinations, dividends and distributions and certain issuances of common stock. The Company has the right, but not the obligation, to redeem shares of Series B-1 Preferred Stock one year after issuance. Holders of Series B-1 Preferred Stock have no voting or dividend rights.

The Company has issued 23,750,000 of Series C-1 Preferred Stock as December 31, 2017. Shares of Series C-1 Preferred Stock are convertible one year after issuance, at any time at the option of the holder, into shares of Common Stock (with a current conversion ratio of one share of Common Stock for each outstanding share). In addition, automatic conversion of shares of Series C-1 Preferred Stock into shares of Common Stock may occur due to public offerings entered into or by written consent of a majority of the holders of Series C-1 Preferred Stock. The conversion price is subject to adjustment under certain customary circumstances, including as a result of stock splits and combinations, dividends and distributions and certain issuances of common stock. The Company has the right, but not the obligation, to redeem shares of Series C-1 Preferred Stock one year after issuance. Holders of Series C-1 Preferred Stock have no voting or dividend rights.

As of December 31, 2017, $1,544,373 of Preferred Stock was converted into 7,556,028 shares of Common Stock.

As of December 31, 2017, the Company issued 1,907,500 shares of Series B Preferred Stock for $381,500 cash.

As of December 31, 2017, the Company issued 12,500 shares of Series B-1 Preferred Stock for a reduction in liabilities of $3,125.

As of December 31, 2017, the Company has issued 8,432,823 shares of Series B-1 Preferred Stock as a $2,108,204 stock interest distribution to Series B Preferred Shareholders.

On September 5, 2017, the Company issued 11,250,000 shares of Series C-1 Preferred Stock related to the purchase of intellectual property, including the patents and technology relating to ammonia synthesis, FeNix coating, and other patents relating to nano-particle application. The Company also purchased a license to use a Nano Sponge technology.

As of December 31, 2016, $580,675 of Preferred Stock was converted into 1,527,527 shares of Common Stock.

For the year ended December 31, 2016, the Company issued 8,126,900 shares of Series B Preferred Stock for $1,625,004 cash.

For the year ended December 31, 2016, the Company has issued 7,093,093 shares of Series B-1 Preferred Stock as a $1,773,273 stock interest distribution to Series B Preferred Shareholders.

On September 28, 2016, the Company issued 12,500,000 shares of Series C-1 Preferred Stock for the joint rights to use, make, sell, and exploit an oil extraction and remediation technology and any patents or trade secrets related to the technology.

Common Stock

The Company is authorized to issue 1,250,000,000 shares of common stock. As of December 31, 2017 and 2016, there were 239,702,491 and 230,383,377 shares of our common stock issued and outstanding. Treasury stock is carried at cost.

As of December 31, 2017, $1,544,373 of Preferred Stock was converted into 7,556,028 shares of Common Stock.

As of December 31, 2017, the convertible debt holders converted $165,401 in convertible debt into 3,763,086 shares of Common Stock.

As of December 31, 2016, $580,675 of Preferred Stock was converted into 1,527,527 shares of Common Stock.

On January 22, 2016, our majority owned subsidiary's shareholder converted its minority interest ($10,000,000) into 20,000,000 shares of Vivakor Common Stock.

8. Income Taxes

As of December 31, 2017 and 2016, the Company has a net deferred tax asset of $2,963,043 and 2,277,266 consisting of net operating loss carryforwards net of an effective offsetting valuation allowance of 100%. Deferred tax assets represent future tax benefits to be received when certain expenses and losses previously recognized in the financial statements become deductible under applicable income tax laws. The realization of deferred tax assets is dependent on future taxable income against which these deductions can be applied. The Company has established the valuation allowance because it is more likely than not that all or a portion of the deferred tax assets will not be realized. Periodic adjustments will be made to the valuation allowance in future periods if there are changes in the evidence of realizability.

9. Related Party Transactions

The Company has a common officer with VivaCeuticals, Inc. As of December 31, 2017 and December 31, 2016 the Company had notes receivable from VivaCeuticals, Inc., in the amount of $1,801,026 and $3,182,750 in a secured lending agreement. Vivaceuticals is being wound down, and the Company has written the receivable down due to the estimated amounts expected to be returned based on available information as Vivaceuticals completes this process. As of December 31, 2017 and 2016, the Company realized an impairment allowance in the amount of $600,342 and $791,383.

VIVAKOR

(949) 281-2606
www.vivakor.com

LAS VEGAS, NEVADA • SALT LAKE CITY, UTAH • IRVINE, CALIFORNIA • DOHA, QATAR